Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.
Identifieur interne : 000638 ( PubMed/Curation ); précédent : 000637; suivant : 000639Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.
Auteurs : Daniel R. Feikin [Kenya] ; Kayla F. Laserson ; Joel Ojwando ; Geoffrey Nyambane ; Victor Ssempijja ; Allan Audi ; Daveline Nyakundi ; Janet Oyieko ; Michael J. Dallas ; Max Ciarlet ; Kathleen M. Neuzil ; Robert F. BreimanSource :
- Vaccine [ 1873-2518 ] ; 2012.
Descripteurs français
- KwdFr :
- Administration par voie orale, Femelle, Fèces (virologie), Gastroentérite (), Gastroentérite (anatomopathologie), Gastroentérite (épidémiologie), Génotype, Humains, Incidence, Infections à VIH (), Infections à VIH (immunologie), Infections à rotavirus (), Infections à rotavirus (anatomopathologie), Infections à rotavirus (épidémiologie), Kenya (épidémiologie), Mâle, Méthode en double aveugle, Nourrisson, Placebo (administration et posologie), Rotavirus (), Rotavirus (génétique), Rotavirus (isolement et purification), Vaccination (), Vaccins anti-rotavirus (administration et posologie), Vaccins anti-rotavirus (immunologie), Vaccins atténués (administration et posologie), Vaccins atténués (immunologie).
- MESH :
- administration et posologie : Placebo, Vaccins anti-rotavirus, Vaccins atténués.
- anatomopathologie : Gastroentérite, Infections à rotavirus.
- génétique : Rotavirus.
- immunologie : Infections à VIH, Vaccins anti-rotavirus, Vaccins atténués.
- isolement et purification : Rotavirus.
- virologie : Fèces.
- épidémiologie : Gastroentérite, Infections à rotavirus, Kenya.
- Administration par voie orale, Femelle, Gastroentérite, Génotype, Humains, Incidence, Infections à VIH, Infections à rotavirus, Mâle, Méthode en double aveugle, Nourrisson, Rotavirus, Vaccination.
- Wicri :
- geographic : Kenya.
English descriptors
- KwdEn :
- Administration, Oral, Double-Blind Method, Feces (virology), Female, Gastroenteritis (epidemiology), Gastroenteritis (pathology), Gastroenteritis (prevention & control), Genotype, HIV Infections (complications), HIV Infections (immunology), Humans, Incidence, Infant, Kenya (epidemiology), Male, Placebos (administration & dosage), Rotavirus (classification), Rotavirus (genetics), Rotavirus (isolation & purification), Rotavirus Infections (epidemiology), Rotavirus Infections (pathology), Rotavirus Infections (prevention & control), Rotavirus Vaccines (administration & dosage), Rotavirus Vaccines (immunology), Vaccination (methods), Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (immunology).
- MESH :
- chemical , administration & dosage : Placebos, Rotavirus Vaccines, Vaccines, Attenuated.
- geographic , epidemiology : Kenya.
- classification : Rotavirus.
- complications : HIV Infections.
- epidemiology : Gastroenteritis, Rotavirus Infections.
- genetics : Rotavirus.
- immunology : HIV Infections, Rotavirus Vaccines, Vaccines, Attenuated.
- isolation & purification : Rotavirus.
- methods : Vaccination.
- pathology : Gastroenteritis, Rotavirus Infections.
- prevention & control : Gastroenteritis, Rotavirus Infections.
- virology : Feces.
- Administration, Oral, Double-Blind Method, Female, Genotype, Humans, Incidence, Infant, Male.
Abstract
Rotavirus gastroenteritis (RVGE) is a leading cause of death in African children. The efficacy of pentavalent rotavirus vaccine (PRV) against severe RVGE evaluated in Ghana, Kenya, and Mali in a randomized, double-blind, placebo-controlled trial, showed a combined regional efficacy of 39.3% (95% confidence interval [CI]: 19.1,54.7) in nearly 2 years of follow-up. This report concentrates on the Kenya findings.
DOI: 10.1016/j.vaccine.2011.08.043
PubMed: 22520137
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000638
Links to Exploration step
pubmed:22520137Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.</title><author><name sortKey="Feikin, Daniel R" sort="Feikin, Daniel R" uniqKey="Feikin D" first="Daniel R" last="Feikin">Daniel R. Feikin</name><affiliation wicri:level="1"><nlm:affiliation>Kenya Medical Research Institute/Centers for Disease Control and Prevention, Research and Public Health Collaboration, Kenya. dfeikin@jhsph.edu</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>Kenya Medical Research Institute/Centers for Disease Control and Prevention, Research and Public Health Collaboration</wicri:regionArea></affiliation></author><author><name sortKey="Laserson, Kayla F" sort="Laserson, Kayla F" uniqKey="Laserson K" first="Kayla F" last="Laserson">Kayla F. Laserson</name></author><author><name sortKey="Ojwando, Joel" sort="Ojwando, Joel" uniqKey="Ojwando J" first="Joel" last="Ojwando">Joel Ojwando</name></author><author><name sortKey="Nyambane, Geoffrey" sort="Nyambane, Geoffrey" uniqKey="Nyambane G" first="Geoffrey" last="Nyambane">Geoffrey Nyambane</name></author><author><name sortKey="Ssempijja, Victor" sort="Ssempijja, Victor" uniqKey="Ssempijja V" first="Victor" last="Ssempijja">Victor Ssempijja</name></author><author><name sortKey="Audi, Allan" sort="Audi, Allan" uniqKey="Audi A" first="Allan" last="Audi">Allan Audi</name></author><author><name sortKey="Nyakundi, Daveline" sort="Nyakundi, Daveline" uniqKey="Nyakundi D" first="Daveline" last="Nyakundi">Daveline Nyakundi</name></author><author><name sortKey="Oyieko, Janet" sort="Oyieko, Janet" uniqKey="Oyieko J" first="Janet" last="Oyieko">Janet Oyieko</name></author><author><name sortKey="Dallas, Michael J" sort="Dallas, Michael J" uniqKey="Dallas M" first="Michael J" last="Dallas">Michael J. Dallas</name></author><author><name sortKey="Ciarlet, Max" sort="Ciarlet, Max" uniqKey="Ciarlet M" first="Max" last="Ciarlet">Max Ciarlet</name></author><author><name sortKey="Neuzil, Kathleen M" sort="Neuzil, Kathleen M" uniqKey="Neuzil K" first="Kathleen M" last="Neuzil">Kathleen M. Neuzil</name></author><author><name sortKey="Breiman, Robert F" sort="Breiman, Robert F" uniqKey="Breiman R" first="Robert F" last="Breiman">Robert F. Breiman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22520137</idno><idno type="pmid">22520137</idno><idno type="doi">10.1016/j.vaccine.2011.08.043</idno><idno type="wicri:Area/PubMed/Corpus">000638</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000638</idno><idno type="wicri:Area/PubMed/Curation">000638</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000638</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.</title><author><name sortKey="Feikin, Daniel R" sort="Feikin, Daniel R" uniqKey="Feikin D" first="Daniel R" last="Feikin">Daniel R. Feikin</name><affiliation wicri:level="1"><nlm:affiliation>Kenya Medical Research Institute/Centers for Disease Control and Prevention, Research and Public Health Collaboration, Kenya. dfeikin@jhsph.edu</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>Kenya Medical Research Institute/Centers for Disease Control and Prevention, Research and Public Health Collaboration</wicri:regionArea></affiliation></author><author><name sortKey="Laserson, Kayla F" sort="Laserson, Kayla F" uniqKey="Laserson K" first="Kayla F" last="Laserson">Kayla F. Laserson</name></author><author><name sortKey="Ojwando, Joel" sort="Ojwando, Joel" uniqKey="Ojwando J" first="Joel" last="Ojwando">Joel Ojwando</name></author><author><name sortKey="Nyambane, Geoffrey" sort="Nyambane, Geoffrey" uniqKey="Nyambane G" first="Geoffrey" last="Nyambane">Geoffrey Nyambane</name></author><author><name sortKey="Ssempijja, Victor" sort="Ssempijja, Victor" uniqKey="Ssempijja V" first="Victor" last="Ssempijja">Victor Ssempijja</name></author><author><name sortKey="Audi, Allan" sort="Audi, Allan" uniqKey="Audi A" first="Allan" last="Audi">Allan Audi</name></author><author><name sortKey="Nyakundi, Daveline" sort="Nyakundi, Daveline" uniqKey="Nyakundi D" first="Daveline" last="Nyakundi">Daveline Nyakundi</name></author><author><name sortKey="Oyieko, Janet" sort="Oyieko, Janet" uniqKey="Oyieko J" first="Janet" last="Oyieko">Janet Oyieko</name></author><author><name sortKey="Dallas, Michael J" sort="Dallas, Michael J" uniqKey="Dallas M" first="Michael J" last="Dallas">Michael J. Dallas</name></author><author><name sortKey="Ciarlet, Max" sort="Ciarlet, Max" uniqKey="Ciarlet M" first="Max" last="Ciarlet">Max Ciarlet</name></author><author><name sortKey="Neuzil, Kathleen M" sort="Neuzil, Kathleen M" uniqKey="Neuzil K" first="Kathleen M" last="Neuzil">Kathleen M. Neuzil</name></author><author><name sortKey="Breiman, Robert F" sort="Breiman, Robert F" uniqKey="Breiman R" first="Robert F" last="Breiman">Robert F. Breiman</name></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Double-Blind Method</term><term>Feces (virology)</term><term>Female</term><term>Gastroenteritis (epidemiology)</term><term>Gastroenteritis (pathology)</term><term>Gastroenteritis (prevention & control)</term><term>Genotype</term><term>HIV Infections (complications)</term><term>HIV Infections (immunology)</term><term>Humans</term><term>Incidence</term><term>Infant</term><term>Kenya (epidemiology)</term><term>Male</term><term>Placebos (administration & dosage)</term><term>Rotavirus (classification)</term><term>Rotavirus (genetics)</term><term>Rotavirus (isolation & purification)</term><term>Rotavirus Infections (epidemiology)</term><term>Rotavirus Infections (pathology)</term><term>Rotavirus Infections (prevention & control)</term><term>Rotavirus Vaccines (administration & dosage)</term><term>Rotavirus Vaccines (immunology)</term><term>Vaccination (methods)</term><term>Vaccines, Attenuated (administration & dosage)</term><term>Vaccines, Attenuated (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale</term><term>Femelle</term><term>Fèces (virologie)</term><term>Gastroentérite ()</term><term>Gastroentérite (anatomopathologie)</term><term>Gastroentérite (épidémiologie)</term><term>Génotype</term><term>Humains</term><term>Incidence</term><term>Infections à VIH ()</term><term>Infections à VIH (immunologie)</term><term>Infections à rotavirus ()</term><term>Infections à rotavirus (anatomopathologie)</term><term>Infections à rotavirus (épidémiologie)</term><term>Kenya (épidémiologie)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Nourrisson</term><term>Placebo (administration et posologie)</term><term>Rotavirus ()</term><term>Rotavirus (génétique)</term><term>Rotavirus (isolement et purification)</term><term>Vaccination ()</term><term>Vaccins anti-rotavirus (administration et posologie)</term><term>Vaccins anti-rotavirus (immunologie)</term><term>Vaccins atténués (administration et posologie)</term><term>Vaccins atténués (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Placebos</term><term>Rotavirus Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Kenya</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Placebo</term><term>Vaccins anti-rotavirus</term><term>Vaccins atténués</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Gastroentérite</term><term>Infections à rotavirus</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Rotavirus</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Gastroenteritis</term><term>Rotavirus Infections</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Rotavirus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Rotavirus</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à VIH</term><term>Vaccins anti-rotavirus</term><term>Vaccins atténués</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term><term>Rotavirus Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Rotavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Rotavirus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Gastroenteritis</term><term>Rotavirus Infections</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Gastroenteritis</term><term>Rotavirus Infections</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Fèces</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Feces</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Gastroentérite</term><term>Infections à rotavirus</term><term>Kenya</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Double-Blind Method</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Incidence</term><term>Infant</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term><term>Femelle</term><term>Gastroentérite</term><term>Génotype</term><term>Humains</term><term>Incidence</term><term>Infections à VIH</term><term>Infections à rotavirus</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Nourrisson</term><term>Rotavirus</term><term>Vaccination</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Kenya</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rotavirus gastroenteritis (RVGE) is a leading cause of death in African children. The efficacy of pentavalent rotavirus vaccine (PRV) against severe RVGE evaluated in Ghana, Kenya, and Mali in a randomized, double-blind, placebo-controlled trial, showed a combined regional efficacy of 39.3% (95% confidence interval [CI]: 19.1,54.7) in nearly 2 years of follow-up. This report concentrates on the Kenya findings.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22520137</PMID><DateCreated><Year>2012</Year><Month>04</Month><Day>23</Day></DateCreated><DateCompleted><Year>2012</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2012</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>30 Suppl 1</Volume><PubDate><Year>2012</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.</ArticleTitle><Pagination><MedlinePgn>A52-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2011.08.043</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Rotavirus gastroenteritis (RVGE) is a leading cause of death in African children. The efficacy of pentavalent rotavirus vaccine (PRV) against severe RVGE evaluated in Ghana, Kenya, and Mali in a randomized, double-blind, placebo-controlled trial, showed a combined regional efficacy of 39.3% (95% confidence interval [CI]: 19.1,54.7) in nearly 2 years of follow-up. This report concentrates on the Kenya findings.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Infants received 3 doses of PRV/placebo at approximately 6-, 10-, and 14-weeks of age. HIV testing was offered to all participants. Data on illness symptoms and signs were collected upon presentation to healthcare facilities, where stools were collected, and analyzed by rotavirus-specific enzyme-linked immunosorbent assay. The primary endpoint was severe RVGE (Vesikari score ≥ 11), occurring ≥ 14 days following the third dose. At monthly home visits, symptoms of illnesses during the past 2 weeks were solicited and limited physical exams were performed; dehydration was defined by WHO's Integrated Management of Childhood Illness.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Vaccine efficacy (VE) against severe RVGE through nearly 2 years of follow-up among 1308 Kenyan children was 63.9% (95% CI: -5.9,89.8). Through the first year of life, VE against severe RVGE was 83.4% (95% CI: 25.5,98.2). From home visits, VE against all-cause gastroenteritis with severe dehydration was 34.4% (95% CI: 5.3,54.6) through the first year and 29.7% (95% CI: 2.5,49.3) through the entire follow-up period. The reduction in incidence of gastroenteritis with severe dehydration in the community during the first year of life (19.0 cases/100 person-years) was almost six times greater than the reduction in severe RVGE presenting to the clinic (3.3/100 person-years). Oral rehydration solution use was lower among PRV recipients (VE 23.1%, 95% CI: 8.8,35.1). An estimated 41% of gastroenteritis with severe dehydration in the first year reported at home was rotavirus-related.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PRV significantly reduced severe RVGE in Kenya. The impact of PRV might be greatest in rural Africa in protecting the many children who develop severe gastroenteritis and cannot access health facilities.</AbstractText><CopyrightInformation>Copyright © 2012. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feikin</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Kenya Medical Research Institute/Centers for Disease Control and Prevention, Research and Public Health Collaboration, Kenya. dfeikin@jhsph.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laserson</LastName><ForeName>Kayla F</ForeName><Initials>KF</Initials></Author><Author ValidYN="Y"><LastName>Ojwando</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Nyambane</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ssempijja</LastName><ForeName>Victor</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Audi</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Nyakundi</LastName><ForeName>Daveline</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Oyieko</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dallas</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Ciarlet</LastName><ForeName>Max</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Neuzil</LastName><ForeName>Kathleen M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Breiman</LastName><ForeName>Robert F</ForeName><Initials>RF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492535">RotaTeq</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022243">Rotavirus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005759" MajorTopicYN="N">Gastroenteritis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007630" MajorTopicYN="N" Type="Geographic">Kenya</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012401" MajorTopicYN="N">Rotavirus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012400" MajorTopicYN="N">Rotavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022243" MajorTopicYN="N">Rotavirus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>08</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22520137</ArticleId><ArticleId IdType="pii">S0264-410X(11)01284-9</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2011.08.043</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000638 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000638 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:22520137
|texte= Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22520137" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |